The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

Bibliography

• Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab 2011;12:57-69
   PubMed Web of Science ®Google Scholar
• Yale JF. Oral antihyperglycemic agents and renal disease: new agents, new concepts. J Am Soc Nephrol 2005;16:7-10
   PubMedGoogle Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-IV inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
   PubMed Web of Science ®Google Scholar
• Sheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12:648-58
   Google Scholar
• Idris S, Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diab Obes Metab 2007;9:153-65
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Fleck PR, Wilson CA, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized double-blind, placebo-controlled study. Diabetes Care 2008;31:2315-17
   PubMed Web of Science ®Google Scholar
• Pratley RE, Reuxch JE, Fleck PR, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009;25:2361-71
   PubMed Web of Science ®Google Scholar
• Pratley RE, Kipnes MS, Fleck PR, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabet Obes Metab 2009;11:167-76
   PubMed Web of Science ®Google Scholar
• Nauck MA, Ellis GC, Fleck PR, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicenter, randomized, double-blind, placebo-controlled study. Int J Clin Pract 2009;63:46-55
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Rendell MS, Gross JL, Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycemia. Diabets Obes Metab 2009;11:1145-52
   PubMed Web of Science ®Google Scholar
• Pratley RE, McCall T, Fleck PR, Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc 2009;57:2011-19
   PubMed Web of Science ®Google Scholar
• Abe M, Okada K, Maruyama T, Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis. Endcrine J 2010;57:581-8
   Google Scholar
• Yu L, Lu S, Lin Y, Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. Biochem. Pharmacol 2010;73:1842-51
   Google Scholar
• Narita T, Katsuura Y, Sato T, Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese type 2 diabetic patients. Diabet Med 2009;26:187-8
   PubMed Web of Science ®Google Scholar
• Seino Y, Fujita T, Hiroi S, Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin 2011;27: S3 21-9
   PubMed Web of Science ®Google Scholar
• Christopher R, Covington P, Davenport M, Pharmacokinetic, pharmacodynamics, and tolerability of single increasing dose of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008;30:513-27
   PubMed Web of Science ®Google Scholar
• Covington P, Christopher R, Davenport M, Pharmacokinetic, pharmacodynamics, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther 2008;30:499-512
   PubMed Web of Science ®Google Scholar
• Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010;70:2051-72
   PubMed Web of Science ®Google Scholar
• Kidney Disease Outcomes Quality Initiative (KDOQI). Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49:S62-73
   Google Scholar
• 2007 American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008;31:S12-54
   Google Scholar
• Inaba M, Okuno S, Kumeda Y, Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007;18:896-903
   PubMed Web of Science ®Google Scholar
• Peacock TP, Shihabi ZK, Bleyer AJ, Comparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis. Kidney Int 2008;73:1062-8
   PubMed Web of Science ®Google Scholar
• Abe M, Matsumoto K. Glycated hemoglobin or glycated albumin for assessment of glycemic control in dialysis patients with diabetes? Nat Clin Pract Nephrol 2008;4:482-3
   PubMedGoogle Scholar
• Shima K, Komatsu M, Kawahara K, Stringent glycemic control prolongs survival in diabetic patients with end-stage renal disease on hemodialysis. Nephrology 2010;15:632-8
   Google Scholar
• Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006;60:1454-70
   PubMed Web of Science ®Google Scholar
• Mathieu C, Bollaerts K. Antihyperglycemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. Int J Clin Pract 2007;61:29-37
   Google Scholar
• Pratley RE, Rosenstock J, Pi-Sunyer FX, Management of type 2 diabetes in treatment-naive elderly patients. Diabetes Care 2007;30:3017-22
   PubMed Web of Science ®Google Scholar